A comparative non randomized study of narrow-band (NB) (312 ± 2 nm) UVB phototherapy versus sequential therapy with oral administration of low-dose Cyclosporin a and NB-UVB phototherapy in patients with severe psoriasis vulgaris

European Journal of Dermatology

Volumn 15, Issue 6, 2005, Pages 470-473

  Calzavara Pinton, Piergiacomo ^a   Leone, Giovanni ^b   Venturini, Marina ^a   Sala, Raffaella ^a   Colombo, Delia ^a   La Parola, Ilaria Lesnoni ^b   Sitzia, Nathalie ^c   Ferraro, Carmela ^b   Picardo, Mauro ^b  

^a Azienda Spedali Civili di Brescia ^*  (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Cyclosporin A; Narrow band UVB radiation; Phototherapy; Psoriasis; Sequential therapy

Indexed keywords

CYCLOSPORIN A;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRURITUS; PSORIASIS VULGARIS; RADIATION DOSE; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADMINISTRATION, ORAL; ADULT; COMBINED MODALITY THERAPY; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; SEVERITY OF ILLNESS INDEX; ULTRAVIOLET THERAPY;

EID: 28244441151     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. van de Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001 ; 26: 356-61.
2. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41(Suppl.): S25-S28.
3. Frederiksson T, Petterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
4. Wainwright NJ, Dawe RS, Ferguson J. Narrowband ultraviolet B (TL-01) phototherapy for psoriasis: which incremental regimen? Br J Dermatol 1998; 139: 410-4.
5. Wellek S. Testing statistical hypothesis of equivalence. London: Chapman and Hall/CRC, 2003.
6. Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF. Association of cyclosporine and 31 1 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol 2004; 17: 401-6.
7. London N, Farmery S, Will E. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-6.
8. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996; 61:715-21.
9. Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA. Does cyclosporin A cause cancer? Nat Med 1999; 5: 714.
10. van den Borne BEEM, Landewe RBM, Haukes I, Schild F, van der Heyden PC, Hazes JM, Hazes JM, Vandenbroucke JP, Zwinderman AH, Goei The HS, Breedveld FC, Bernelot, Moens HJ, Kluin PM, Dijkmans BA. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1930-7.
11. Arellano F, Krupp P. Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Br J Rheumatol 1993; 32(Suppl 1 ): 72-5.
12. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al. Risk of malignancies in psoriatic patients, treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 211-6.
13. van de Kerkhof PC, de Rooij MJ. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol 1997; 130: 275-8.
14. Mercil I, Stern S. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042-5.
15. Godar DE. Preprogrammed and programmed cell death mechanisms apoptosis: UV-induced immediate and delayed apoptosis. Photochem Photobiol 1996; 63: 825-30.
16. Canton M, Caffieri S, Dall' Acqua F, Di Lisa F. PUVA-induced apoptosis involves mitochondrial dysfunction caused by the opening of the permeability transition pore. FEBS Lett 2002; 522: 168-72.